# Onconase Induces Apoptosis in Dabrafenib-Resistant Melanoma Cell Lines Through Dysregulation of ROS Homeostasis, Antioxidant Protein Expression, and Mitochondrial Dynamics

**Authors:** Carlotta Passarini, Alessia Cardile, Filippo Zuanetti, Valentina Zanrè, Raffaella Pacchiana, Adriana Celesia, Federica Danzi, Alessandra Fiore, Giovanni Gotte, Marta Menegazzi

PMC · DOI: 10.3390/ijms27041638 · International Journal of Molecular Sciences · 2026-02-07

## TL;DR

Onconase kills melanoma cells resistant to BRAF inhibitors by disrupting antioxidant systems, mitochondrial function, and survival signals.

## Contribution

This study reveals how Onconase induces apoptosis in BRAF inhibitor-resistant melanoma cells through ROS dysregulation and mitochondrial dysfunction.

## Key findings

- Onconase increases ROS levels and downregulates NRF2 and antioxidant proteins in resistant melanoma cells.
- Onconase impairs mitochondrial biogenesis and fission, leading to enlarged mitochondria and reduced autophagy.
- Onconase triggers apoptosis via caspase-9 activation and downregulates antiapoptotic protein survivin.

## Abstract

Advanced melanoma remains difficult to treat due to its intrinsic resistance to conventional therapies and the frequent development of acquired resistance to targeted agents, such as BRAF inhibitors. Onconase (ONC), an amphibian ribonuclease with established antitumor activity, had been previously shown to have selective cytotoxicity toward melanoma cells. In this study, we investigated the molecular mechanisms underlying ONC-induced cytotoxicity in BRAF-mutated melanoma cell lines that are either sensitive or resistant to the BRAF inhibitor dabrafenib. We focused on oxidative stress regulation, mitochondrial dynamics, and cell death-related signaling pathways. ONC treatment resulted in a marked increase in reactive oxygen species (ROS) levels, concomitant with a pronounced downregulation of NRF2 and multiple NRF2-dependent antioxidant proteins. These effects were particularly evident in dabrafenib-resistant melanoma cells. In parallel, ONC impaired mitochondrial plasticity by inhibiting mitochondrial biogenesis and fission, as evidenced by reduced PGC1α, DRP1, and FIS1 expression. Confocal analysis confirmed the presence of more enlarged mitochondria in ONC-treated cells. Mitophagy and autophagy are hindered by ONC due to the downregulation of PINK1, beclin1, ATG3 expression, as well as the lack of LC3B activation. These mitochondrial defects were associated with mitochondrial-dependent apoptosis, characterized by caspase-9 activation and strong downregulation of the antiapoptotic protein survivin. Lipid peroxidation was also induced by ONC, especially in the A375 cell line. Additionally, ONC inhibited key proliferation-related signaling pathways, including STAT3 and NF-κB, and reduced cyclin-dependent kinase 1, 2, and 4 activities. Collectively, these findings demonstrate that ONC disrupts redox homeostasis, mitochondrial function, and survival signaling in melanoma cells, exerting particularly potent effects in BRAF inhibitor-resistant populations. This study provides mechanistic insight into the anti-melanoma activity of ONC and supports its potential therapeutic application in drug-resistant melanoma.

## Linked entities

- **Genes:** GABPA (GA binding protein transcription factor subunit alpha) [NCBI Gene 2551], PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891], CRMP1 (collapsin response mediator protein 1) [NCBI Gene 1400], FIS1 (fission, mitochondrial 1) [NCBI Gene 51024], PINK1 (PTEN induced kinase 1) [NCBI Gene 65018], BECN1 (beclin 1) [NCBI Gene 8678], ATG3 (autophagy related 3) [NCBI Gene 64422], MAP1LC3B (microtubule associated protein 1 light chain 3 beta) [NCBI Gene 81631], birc5a (baculoviral IAP repeat containing 5a) [NCBI Gene 373110], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Proteins:** Casp9 (caspase 9), birc5a (baculoviral IAP repeat containing 5a)
- **Chemicals:** dabrafenib (PubChem CID 44462760)
- **Diseases:** melanoma (MONDO:0005105)

## Full-text entities

- **Genes:** AXL (AXL receptor tyrosine kinase) [NCBI Gene 558] {aka ARK, AXL3, JTK11, Tyro7, UFO}, MAP1LC3B (microtubule associated protein 1 light chain 3 beta) [NCBI Gene 81631] {aka ATG8F, LC3B, MAP1A/1BLC3, MAP1LC3B-a}, MIR20A (microRNA 20a) [NCBI Gene 406982] {aka C13orf25, MIR20, MIRH1, MIRHG1, MIRN20, MIRN20A}, MFN2 (mitofusin 2) [NCBI Gene 9927] {aka CMT2A, CMT2A2, CMT2A2A, CMT2A2B, CPRP1, HMSN6A}, CRMP1 (collapsin response mediator protein 1) [NCBI Gene 1400] {aka CRMP-1, DPYSL1, DRP-1, DRP1, ULIP-3}, GSTP1 (glutathione S-transferase pi 1) [NCBI Gene 2950] {aka DFN7, FAEES3, GST3, GSTP, GSTP1-1, HEL-S-22}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, H2AX (H2A.X variant histone) [NCBI Gene 3014] {aka H2A.X, H2A/X, H2AFX}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, Mir34a (microRNA 34a) [NCBI Gene 723848] {aka Mirn34a, mir-34a, mmu-mir-34a}, MIR34A (microRNA 34a) [NCBI Gene 407040] {aka MIRN34A, miRNA34A, mir-34, mir-34a}, Anxa5 (annexin A5) [NCBI Gene 11747] {aka Anx5, CPB-I}, ATG3 (autophagy related 3) [NCBI Gene 64422] {aka APG3, APG3-LIKE, APG3L, PC3-96, hApg3}, COX4I1 (cytochrome c oxidase subunit 4I1) [NCBI Gene 1327] {aka COX IV-1, COX4, COX4-1, COXIV, COXIV-1, MC4DN16}, DACT1 (dishevelled binding antagonist of beta catenin 1) [NCBI Gene 51339] {aka DAPPER, DAPPER1, DPR1, FRODO, HDPR1, TBS2}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, BECN1 (beclin 1) [NCBI Gene 8678] {aka ATG6, VPS30, beclin1}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, ATP5F1B (ATP synthase F1 subunit beta) [NCBI Gene 506] {aka ATP5B, ATPMB, ATPSB, DYT38, HEL-S-271, HUMOP2}, MIR29A (microRNA 29a) [NCBI Gene 407021] {aka MIRN29, MIRN29A, hsa-mir-29, hsa-mir-29a, miRNA29A, mir-29a}, OPA1 (OPA1 mitochondrial dynamin like GTPase) [NCBI Gene 4976] {aka BERHS, MGM1, MTDPS14, MTDPS14A, MTDPS14B, NPG}, CDK4 (cyclin dependent kinase 4) [NCBI Gene 1019] {aka CMM3, MCPH31, PSK-J3}, Parp1 (poly (ADP-ribose) polymerase family, member 1) [NCBI Gene 11545] {aka 5830444G22Rik, ARTD1, Adprp, Adprt1, PARP, PPOL}, UQCRC1 (ubiquinol-cytochrome c reductase core protein 1) [NCBI Gene 7384] {aka D3S3191, PKNPY, QCR1, UQCR1}, GSR (glutathione-disulfide reductase) [NCBI Gene 2936] {aka CNSHA10, GR, GSRD, HEL-75, HEL-S-122m}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, FTH1 (ferritin heavy chain 1) [NCBI Gene 2495] {aka FHC, FTH, FTHL6, HFE5, NBIA9, PIG15}, RNASE1 (ribonuclease A family member 1, pancreatic) [NCBI Gene 6035] {aka RAC1, RIB1, RNS1}, Casp9 (caspase 9) [NCBI Gene 12371] {aka APAF-3, CASP-9, Caspase-9, ICE-LAP6, Mch6}, EIF2AK3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 9451] {aka PEK, PERK, WRS}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 397013] {aka PGC1, PGC1A, PPARGC-1, PPARGC1}, SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657] {aka CCBR1, xCT}, FIS1 (fission, mitochondrial 1) [NCBI Gene 51024] {aka CGI-135, TTC11}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, PINK1 (PTEN induced kinase 1) [NCBI Gene 65018] {aka BRPK, PARK6}, DNM1L (dynamin 1 like) [NCBI Gene 10059] {aka DLP1, DRP1, DVLP, DYMPLE, EMPF, EMPF1}, GCLM (glutamate-cysteine ligase modifier subunit) [NCBI Gene 2730] {aka GLCLR}, Braf (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 109880] {aka 9930012E13Rik, B-raf, Braf-2, Braf2, C230098H17, D6Ertd631e}, S100A4 (S100 calcium binding protein A4) [NCBI Gene 6275] {aka 18A2, 42A, CAPL, FSP1, MTS1, P9KA}, CDK2 (cyclin dependent kinase 2) [NCBI Gene 1017] {aka CDKN2, p33(CDK2)}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, CDK1 (cyclin dependent kinase 1) [NCBI Gene 983] {aka CDC2, CDC28A, P34CDC2}, FOSL1 (FOS like 1, AP-1 transcription factor subunit) [NCBI Gene 8061] {aka FRA, FRA1, fra-1}, TOMM20 (translocase of outer mitochondrial membrane 20) [NCBI Gene 9804] {aka MAS20, MOM19, TOM20}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, SOD2 (superoxide dismutase 2) [NCBI Gene 6648] {aka GC1, GClnc1, IPO-B, IPOB, MNSOD, MVCD6}, MFN1 (mitofusin 1) [NCBI Gene 55669] {aka hfzo1, hfzo2}, Birc5 (baculoviral IAP repeat-containing 5) [NCBI Gene 11799] {aka AAC-11, Api4, TIAP, survivin40}
- **Diseases:** leukemic (MESH:D007938), tumorigenic (MESH:D002471), metastasis (MESH:D009362), mitochondrial defects (MESH:C565376), cytotoxic (MESH:D064420), lymphoma (MESH:D008223), pancreatic adenocarcinoma (MESH:D010190), glioma (MESH:D005910), Melanoma (MESH:D008545), injury to (MESH:D014947), cancer (MESH:D009369), skin cancer (MESH:D012878), cutaneous (MESH:D018366), malignant mesothelioma (MESH:D000086002), non-small-cell lung cancer (MESH:D002289), genetic dysfunction (MESH:D030342)
- **Chemicals:** HEPES (MESH:D006531), sodium phosphate (MESH:C018279), glycerol (MESH:D005990), phenol red (MESH:D010637), crystal violet (MESH:D005840), PI (MESH:D011419), BODIPY  581/591 C11 (-), Superoxide (MESH:D013481), oil (MESH:D009821), Ser (MESH:D012694), oxidized glutathione (MESH:D019803), trichloroacetic acid (MESH:D014238), heme (MESH:D006418), ubiquinone (MESH:D014451), PFA (MESH:C003043), DAB (MESH:C561627), Lipid (MESH:D008055), glutathione (MESH:D005978), SRB (MESH:C022027), MitoSOX (MESH:C521281), ROS (MESH:D017382), ubiquinol (MESH:C003741), glucose (MESH:D005947), PVDF (MESH:C024865), ZnSO4 (MESH:D019287), Tween 20 (MESH:D011136), PBS (MESH:D007854), sodium acetate (MESH:D019346), KCl (MESH:D011189), zinc (MESH:D015032), dacarbazine (MESH:D003606), NaCl (MESH:D012965), Met (MESH:D008715), biliverdin (MESH:D001664), pentose phosphate (MESH:D010428), polyacrylamide (MESH:C016679), vemurafenib (MESH:D000077484), potassium phosphate (MESH:C013216), bromophenol blue (MESH:D001978), Z-VAD-FMK (MESH:C096713), EDTA (MESH:D004492), carbon monoxide (MESH:D002248), MDC (MESH:C008542), encorafenib (MESH:C000601108), iron (MESH:D007501), MitoTracker Green FM (MESH:C111472), MitoSOX  Red (MESH:C000597839), water (MESH:D014867), HCl (MESH:D006851), SDS (MESH:D012967), acetic acid (MESH:D019342), CaCl2 (MESH:D002122)
- **Species:** Homo sapiens (human, species) [taxon 9606], Bos taurus (bovine, species) [taxon 9913], Vibrio proteolyticus (species) [taxon 671], Escherichia coli (E. coli, species) [taxon 562], Lithobates pipiens (northern leopard frog, species) [taxon 8404], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** glutamate-cysteine, His/Lys, A375R, BRAFV600E, A375
- **Cell lines:** pET-22b — Mus musculus (Mouse), Adenoma of the mouse pulmonary system, Cancer cell line (CVCL_5U98), A375 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_6233), 29380-1 — Mus musculus (Mouse), Hybridoma (CVCL_C7RB), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232), SRB — Opodiphthera eucalypti (Emperor gum moth), Spontaneously immortalized cell line (CVCL_C2VY), AAP — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_EQ30), FO-1 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_5619)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12941091/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941091/full.md

## References

82 references — full list in the complete paper: https://tomesphere.com/paper/PMC12941091/full.md

---
Source: https://tomesphere.com/paper/PMC12941091